KEZAR LIFE SCIENCES, INC.

(KZR)
  Report
Delayed Nasdaq  -  05/16 04:00:00 pm EDT
6.020 USD   +4.70%
05/13KEZAR LIFE SCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/13Kezar Life Sciences, Inc. Announces Executive Changes
CI
05/12KEZAR LIFE SCIENCES, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
All news about KEZAR LIFE SCIENCES, INC.
05/13KEZAR LIFE SCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
05/13Kezar Life Sciences, Inc. Announces Executive Changes
CI
05/12KEZAR LIFE SCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
05/12Earnings Flash (KZR) KEZAR LIFE SCIENCES Posts Q1 Loss $-0.26
MT
05/12Kezar Life Sciences Reports First Quarter 2022 Financial Results and Provides Business ..
BU
05/12Kezar Life Sciences, Inc. Reports Earnings Results for the First Quarter Ended March 31..
CI
05/05Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
BU
05/04Top Midday Decliners
MT
05/04Wells Fargo Adjusts Kezar Life Sciences' Price Target to $14 from $19, Keeps Overweight..
MT
05/04SECTOR UPDATE : Health Care Stocks Climb Pre-Bell Wednesday
MT
05/04SECTOR UPDATE : Health Care
MT
05/04Wall Street Set for Higher Open Ahead of Fed Funds Rate Announcement, ISM's Services In..
MT
05/04Top Premarket Decliners
MT
05/04Kezar Life Sciences Phase 2 Study of Autoimmune Myositis Diseases Fails to Differentiat..
MT
05/03KEZAR LIFE SCIENCES, INC. : Results of Operations and Financial Condition, Other Events, F..
AQ
05/03Kezar Announces Topline Results from PRESIDIO Trial of Zetomipzomib for the Treatment o..
BU
05/03Kezar Life Sciences, Inc. Announces Topline Results from PRESIDIO Trial of Zetomipzomib..
CI
04/15Kezar Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
BU
03/23Kezar Life Sciences Shares Rise After Director Boosts Stake
MT
03/23INSIDER BUY : Kezar Life Sciences
MT
03/18HC Wainwright Adjusts Kezar Life Sciences' Price Target to $22 From $20, Keeps Buy Rati..
MT
03/18Kezar Life Sciences Q4 Net Loss Widens
MT
03/17KEZAR LIFE SCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
03/17KEZAR LIFE SCIENCES : Reports Fourth Quarter and Year-End 2021 Financial Results and Provi..
PU
03/17Kezar Life Sciences, Inc. Reports Earnings Results for the Full Year Ended December 31,..
CI
03/17Earnings Flash (KZR) KEZAR LIFE SCIENCES Reports Q4 Loss $-0.25
MT
03/17Kezar Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business ..
BU
03/17Kezar Life Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended Decembe..
CI
03/02Kezar Life Sciences to Participate in Cowen 42nd Annual Health Care Conference
BU
01/07KEZAR LIFE SCIENCES, INC. : Results of Operations and Financial Condition, Change in Direc..
AQ
2021KEZAR LIFE SCIENCES, INC. : Termination of a Material Definitive Agreement, Results of Ope..
AQ
2021KEZAR LIFE SCIENCES, INC.(NASDAQGS : KZR) added to S&P Biotechnology Select Industry Index
CI
2021KEZAR LIFE SCIENCES, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Kezar Appoints Courtney Wallace to its Board of Directors
BU
2021Kezar Life Sciences, Inc. Announce Directorate Changes
CI
2021Wells Fargo Starts Kezar Life Sciences at Overweight With $19 Price Target
MT
2021Health Care Stocks Ease Slightly At Tuesday Close
MT
2021Health Care Stocks Helping Boost Tuesday Markets
MT
2021Top Midday Gainers
MT
2021HC Wainwright Adjusts Price Target on Kezar Life Sciences to $20 from $12, Keeps Buy Ra..
MT
2021Wall Street Treads Water Pre-Bell, October Retail Sales Top Estimates
MT
2021Health Care Stocks Mixed Pre-Bell Tuesday
MT
2021SECTOR UPDATE : Health Care
MT
2021Top Premarket Gainers
MT
2021Kezar Life Sciences Sees Clinically Meaningful Benefit in Phase 2 Portion of Lupus Neph..
MT
2021KEZAR LIFE SCIENCES, INC. : Regulation FD Disclosure, Other Events, Financial Statements a..
AQ
2021TRANSCRIPT : Kezar Life Sciences, Inc. - Analyst/Investor Day
CI
2021Kezar Life Sciences Announces Interim Results from the MISSION Phase 2 Trial in Patient..
BU
2021Kezar Life Sciences, Inc. Sciences Announces Interim Results from the Mission Phase 2 T..
CI
2021Kezar Life Sciences to Present at the Jefferies London Healthcare Conference
BU
2021Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc.
BU
2021Oxford Finance Provides $50 Million Credit Facility to Kezar Life Sciences, Inc
CI
2021KEZAR LIFE SCIENCES, INC. Management's Discussion and Analysis of Financial Condition ..
AQ
2021Kezar Reports Third Quarter Financial Results and Provides Business Update - Form 8-K
PU
2021KEZAR LIFE SCIENCES, INC. : Entry into a Material Definitive Agreement, Results of Operati..
AQ
2021Earnings Flash (KZR) KEZAR LIFE SCIENCES Reports Q3 Loss $-0.28
MT
2021Kezar Reports Third Quarter Financial Results and Provides Business Update
BU
2021Kezar Life Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Month..
CI
2021Kezar to Host Virtual Investor and Analyst Day on November 15, 2021
BU
2021Top Premarket Decliners
MT
2021Kezar Life Sciences Doses First Patient in Phase 1 Trial of Anti-Tumor Agent
MT
2021Kezar Announces First Patient Dosed in Phase 1 Trial of KZR-261 in Advanced Solid Tumor..
BU
2021Kezar Life Sciences, Inc. Announces First Patient Dosed in Phase 1 Trial of KZR-261 in ..
CI
2021KEZAR LIFE SCIENCES : Names VP of Investor Relations, External Affairs
MT
2021KEZAR LIFE SCIENCES : Appoints Gitanjali Jain as Vice President, Investor Relations and Ex..
BU
2021KEZAR LIFE SCIENCES : to Participate in Two Upcoming Investor Conferences
BU
2021UPDATE : Kezar Life Sciences Achieves Enrollment Milestone in Phase 2 Trial of Myositis Th..
MT
2021KEZAR LIFE SCIENCES : Achieves Enrollment Milestone in Phase 2 Trial of Myositis Therapeut..
MT
2021KEZAR LIFE SCIENCES : Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical ..
BU
2021Kezar Life Sciences Announces Completion of Enrollment of Its Phase 2 PRESIDIO Clinical..
CI
2021NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
2021KEZAR LIFE SCIENCES : Management's Discussion and Analysis of Financial Condition and Resu..
AQ
2021KEZAR LIFE SCIENCES : Reports Second Quarter Financial Results and Provides Business Updat..
PU
2021KEZAR LIFE SCIENCES : Earnings Flash (KZR) KEZAR LIFE SCIENCES Posts Q2 Loss $-0.25
MT
2021KEZAR LIFE SCIENCES : Reports Second Quarter Financial Results and Provides Business Updat..
BU
1  2  3Next
Upcoming event on KEZAR LIFE SCIENCES, INC.